>北美急性呼吸窘迫综合征 (ARDS) 市场，按原因（2019 年冠状病毒病 (COVID-19)、败血症、吸入有害物质、严重肺炎等）、类型（诊断和治疗）、给药途径（口服、肠外和其他）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、医院药房、零售药房、网上药房等）、国家（美国、加拿大和墨西哥）划分的行业趋势和预测到 2029 年。
市场分析和见解：北美急性呼吸窘迫综合征 (ARDS) 市场
北美急性呼吸窘迫综合征 (ARDS) 市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 10.5%，预计到 2029 年将达到 75.0048 亿美元。COVID-19 患病率的不断上升推动了急性呼吸窘迫综合征 (ARDS) 市场的增长。
急性呼吸窘迫综合征 (ARDS) 是一种危及生命的肺部损伤，会导致液体渗入肺部。大多数患有 ARDS 的人已经因为创伤或 COVID-19 等疾病住院。这种综合征通常发生在肺部微小的弹性气囊（称为肺泡）中积液时。这种液体积聚会导致血液中的氧气减少。这使得器官无法获得足够的氧气来维持正常功能。患有其他疾病的人在诱发损伤或感染后的几小时到几天内会患上 ARDS。死亡风险随着年龄的增长而增加，并且根据病情的严重程度，患者很难从该综合征中幸存下来。严重的疾病或损伤导致肺膜囊受损，从而导致 ARDS。上述疾病最常见的潜在原因包括败血症、吸入有害物质、严重肺炎、头部、胸部或其他重大损伤、2019 年冠状病毒病 (COVID-19) 等。
急性肺损伤的患病率和发病率不断上升、ARDS 的多种风险因素以及患有 ARDS 的新冠肺炎患者人数的增加，这些因素推动了急性呼吸窘迫综合征 (ARDS) 市场的发展。预计推动北美急性呼吸窘迫综合征 (ARDS) 市场增长的其他因素包括空气污染和生活方式相关疾病的增加以及导致 ARDS 的事故率和创伤率的增加。
However, the factors such as the complications associated with treatments, high cost of devices and treatments are hampering the growth of the North America acute respiratory distress syndrome (ARDS) market. On the other hand, the growing geriatric population, rising healthcare expenditure and strategic Initiatives by market players act as an opportunity for the growth of the North America acute respiratory distress syndrome (ARDS) market. The stringent Regulations for approval and multiple challenges faced by ICU nurses is the key market challenge faced in the North America acute respiratory distress syndrome (ARDS) market.
The acute respiratory distress syndrome (ARDS) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the acute respiratory distress syndrome (ARDS) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Acute Respiratory Distress Syndrome (ARDS) Market Scope and Market Size
The acute respiratory distress syndrome (ARDS) market is segmented on basis of cause, type, route of administration, end users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cause, the North America acute respiratory distress syndrome (ARDS) market is segmented into coronavirus disease 2019 (COVID-19), sepsis, inhalation of harmful substances, severe pneumonia and others. In 2022, coronavirus disease 2019 (COVID-19) segment is expected to dominate the market as the disease has spread all over the region with huge death rates.
- On the basis of type, the North America acute respiratory distress syndrome (ARDS) market is segmented into diagnosis and treatment. In 2022, diagnosis segment is expected to dominate the market as people were more aware of the timely diagnosis for proper treatment for deadly disorder.
- On the basis of route of administration, the North America acute respiratory distress syndrome (ARDS) market is segmented into oral, parenteral and others. The parenteral segment is further segmented into intramuscular and intravenous. In 2022, parenteral segment is expected to dominate the market due to high range of products getting approved by FDA with increasing number of products under pipeline.
- 根据最终用户，北美急性呼吸窘迫综合征 (ARDS) 市场分为医院、专科诊所、家庭医疗保健和其他。由于发达国家的高科技发展，预计到 2022 年，医院部门将占据市场主导地位。
- 根据分销渠道，北美急性呼吸窘迫综合征 (ARDS) 市场分为直接招标、医院药房、零售药房、网上药房和其他。2022 年，直接招标市场预计将占据市场主导地位，因为参与者正在采取战略举措扩大其分销渠道以实现全球供应。
急性呼吸窘迫综合征 (ARDS) 市场国家级分析
对急性呼吸窘迫综合征 (ARDS) 市场进行了分析，并按国家/地区提供了市场规模信息，包括上述五个值得注意的部分，例如原因、类型、给药途径、最终用户和分销渠道。
急性呼吸窘迫综合征 (ARDS) 市场报告涉及的国家包括美国、加拿大和墨西哥。
由于政府和组织的支持不断增加，预计美国的医院部门将在 2022 年至 2029 年的预测期内以最高增长率增长。由于慢性呼吸道疾病病例增加且正确诊断的采用率高，加拿大的医院部门在市场中占据第二大主导地位。墨西哥在市场增长方面位居第三，由于 COVID-19 的出现，该国开设了越来越多的新医院基础设施，因此医院部门在该国占据主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
主要市场参与者不断增加的战略活动，以提高对急性呼吸窘迫综合征 (ARDS) 治疗的认识，正在推动急性呼吸窘迫综合征 (ARDS) 市场的增长
急性呼吸窘迫综合征 (ARDS) 市场还为您提供特定市场中每个国家增长的详细市场分析。此外，它还提供有关市场参与者战略及其地理分布的详细信息。数据适用于 2011 年至 2020 年的历史时期。
竞争格局和急性呼吸窘迫综合征 (ARDS) 市场份额分析
急性呼吸窘迫综合征 (ARDS) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对急性呼吸窘迫综合征 (ARDS) 市场的关注有关。
从事急性呼吸窘迫综合征 (ARDS) 的主要公司包括 Drägerwerk AG & Co. KGaA、Fisher & Paykel Healthcare Limited.、LivaNova PLC、Gilead Sciences, Inc.、Fresenius SE & Co. KGaA、Armstrong Medical、Smiths Medical (ICU Medical, Inc. 的一部分)、ResMed、ALung Technologies, Inc.、Medtronic、F. Hoffmann-La Roche Ltd、Hamilton Medical、nice Neotech Medical Systems Pvt. Ltd.、Pfizer Inc.、WEINMANN Emergency Medical Technology GmbH + Co. KG、NIPRO、Terumo Medical Corporation、Getinge AB.、EUROSETS 以及其他国内公司。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
全球各地的公司也签订了许多合同和协议，这也加速了急性呼吸窘迫综合征 (ARDS) 市场的发展。
例如，
- 2021 年 5 月，美敦力宣布推出 SonarMed 气道监测系统。该系统利用声学技术检查气管插管是否堵塞。这有助于该公司扩大其产品组合。
- 2020 年 7 月，F. Hoffman-La Roche Ltd 宣布推出 SARS-CoV-2 快速抗体检测。该检测是与 SD Biosenseor, Inc. 合作推出的。这有助于该公司扩大其产品组合。
市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在急性呼吸窘迫综合征市场的影响力，这也为组织的利润增长带来了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CAUSE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS
5.1 REGULATION IN U.S.:
5.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA
5.3 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES
5.4 LABELING OF MODIFIED DEVICES
5.5 REGULATION IN EUROPE:
5.6 REGULATION IN INDIA:
5.7 REGULATION IN JAPAN:
6 REGIONAL SUMMARY
6.1 NORTH AMERICA REGION
6.2 EUROPE REGION
6.3 ASIA-PACIFIC
6.4 SOUTH AMERICA
6.5 MIDDLE EAST AND AFRICA
7 PIPELINE ANALYSIS
8 INSURANCE REIMBURSEMENT
8.1 CENTER FOR MEDICARE SERVICES (CMS)–ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION)
8.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION
8.3 ABBOTT CODING GUIDE FOR ECMO
8.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS)
8.5 CERN HEALTH INSURANCE SCHEME
8.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) – (MEDICARE & MEDICAID)
8.7 AMERICAN HOSPITAL ASSOCIATION
8.8 CONCLUSION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY
9.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS
9.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS
9.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES
9.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS
9.2 RESTRAINTS
9.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS
9.2.2 HIGH COST OF DEVICE AND TREATMENTS
9.2.3 LACK OF SKILLED WORKFORCE
9.3 OPPORTUNITIES
9.3.1 GROWING GERIATRIC POPULATION
9.3.2 RISING HEALTHCARE EXPENDITURE
9.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
9.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME
9.4 CHALLENGES
9.4.1 STRINGENT RULES & REGULATIONS
9.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES
10 IMPACT OF COVID-19 PANDEMIC ON THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 IMAGING TESTS
11.2.1.1 CHEST X-RAY
11.2.1.2 CT SCAN
11.2.1.3 ULTRASOUND
11.2.1.4 OTHERS
11.2.2 BLOOD TEST
11.2.3 RESPIRATORY RATE
11.2.4 SPO2 TEST
11.2.5 OTHERS
11.3 TREATMENT
11.3.1 MECHANICAL VENTILATION
11.3.1.1 HIGH-FLOW NASAL O2
11.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE
11.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE
11.3.1.4 PRONE POSITIVE VENTILATION
11.3.1.5 OTHERS
11.3.2 CORTICOSTEROIDS
11.3.2.1 METHYLPREDNISOLONE
11.3.2.2 DEXAMETHASONE
11.3.2.3 OTHERS
11.3.3 ANTIVIRAL MEDICATION
11.3.3.1 REMDESIVIR
11.3.3.2 COMBINATION DRUGS
11.3.3.3 OTHERS
11.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
11.3.5 TOCILIZUMAB
11.3.6 OTHERS
12 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.2.1 INTRAVENOUS
12.2.2 INTRAMUSCULAR
12.3 ORAL
12.4 OTHERS
13 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE
13.1 OVERVIEW
13.2 CORONAVIRUS DISEASE 2019 (COVID-19)
13.3 SEPSIS
13.4 INHALATION OF HARMFUL SUBSTANCES
13.5 SEVERE PNEUMONIA
13.6 OTHERS
14 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 GILEAD SCIENCES INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUS ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 TERUMO CORPORATION
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUS ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 GETINGE AB
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUS ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LIVANOVA PLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MEDTRONIC
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ALUNG TECHNOLOGIES, INC
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ARMSTRONG MEDICAL
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BESMED HEALTH BUSINESS CORP.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 DRÄGERWERK AG & CO. KGAA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 EUROSETS
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 F. HOFFMANN-LA ROCHE LTD
19.11.1 COMPANY SNAPSHOT
19.11.2 RECENT ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 FISHER & PAYKEL HEALTHCARE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 FRESENIUS SE & CO. KGAA
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUS ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 HAMILTON MEDICAL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 NIPRO
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUS ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 PFIZER INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUS ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 RESMED
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 SMITHS MEDICAL
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUS ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: PIPELINE ANALYSIS
TABLE 2 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA ORAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA CORONAVIRUS DISEASE 2019 (COVID-19) IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA SEPSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA INHALATION OF HARMFUL SUBSTANCES IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA SEVERE PNEUMONIA IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA HOSPITALS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA HOME HEALTHCARE IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA DIRECT TENDER IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA HOSPITAL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA RETAIL PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA ONLINE PHARMACY IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 46 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 U.S. DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 U.S. IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 U.S. TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 U.S. CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 U.S. MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 54 U.S. PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 55 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 U.S. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 57 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 58 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 CANADA DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CANADA IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CANADA TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 CANADA ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 CANADA CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CANADA MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 66 CANADA PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 CANADA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE, 2020-2029 (USD MILLION)
TABLE 70 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 MEXICO DIAGNOSIS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 MEXICO IMAGING TESTS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 MEXICO TREATMENT IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 MEXICO ANTIVIRAL MEDICATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 MEXICO CORTICOSTEROIDS IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 MEXICO MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 78 MEXICO PARENTERAL IN ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 79 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SEGMENTATION
FIGURE 11 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS IS EXPECTED TO DRIVE THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CORONAVIRUS DISEASE 2019 (COVID-19) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET
FIGURE 15 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2021
FIGURE 16 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 17 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 20 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 21 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 22 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 23 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2021
FIGURE 24 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, 2020-2029 (USD MILLION)
FIGURE 25 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, CAGR (2022-2029)
FIGURE 26 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2021
FIGURE 28 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 29 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: DISTRIBUTION CHANNEL, 2021
FIGURE 32 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 33 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 34 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: SNAPSHOT (2021)
FIGURE 36 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021)
FIGURE 37 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 38 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 39 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: BY CAUSE (2022 & 2029)
FIGURE 40 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
